Cogent reports Q3 2026 results, three bezuclastinib PDUFA dates aheadNov 5Quarterly updatebezuclastinibCogent Biosciences, Inc.
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
BMS registers Phase 1 CAR T cell trial in kidney cancer; adds mavacamten real-world studyOct 1Weekly roundup, 5 itemsBristol Myers SquibbgolcadomideUpdated
Cogent Biosciences reports Q2 2026 results, two bezuclastinib PDUFA dates aheadAug 10Quarterly updatebezuclastinibCogent Biosciences, Inc.
Cogent Biosciences files $400 million stock offering under existing at-the-market programAug 10FinancingbezuclastinibCogent Biosciences, Inc.
GSK posts bepirovirsen QT results; registers Mo-Rez ovarian, endometrial Phase 3 trialsJul 10Weekly roundup, 6 itemsbepirovirsencamlipixant